{"product_id":"ntra-vrio-analysis","title":"Natera, Inc. (NTRA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Natera, Inc. (NTRA)'s competitive edge with this distilled VRIO analysis. We cut straight to the core, examining the Value, Rarity, Inimitability, and Organization of their key assets to reveal the true source of their market strength, as summarized in \u0026amp;O4\u0026amp;. Read on immediately to grasp the critical factors that define their success and what it means for their future performance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 1. Extensive Intellectual Property Estate\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at Natera, Inc.'s patent estate as a core defense mechanism in the competitive liquid biopsy space. The takeaway here is that while the sheer volume of patents creates a significant initial barrier, the recent litigation outcomes show that specific claims are vulnerable, meaning the advantage is strong but not entirely sustained.\u003c\/p\u003e\n\n\u003cp\u003eThe foundation of this strength is the sheer scale of protection. Natera maintains a portfolio of over \u003cstrong\u003e500\u003c\/strong\u003e issued or pending patents worldwide, covering their core cell-free DNA (cfDNA) testing methods, especially for molecular residual disease (MRD) with their Signatera test. Also, their tests are supported by more than \u003cstrong\u003e325\u003c\/strong\u003e peer-reviewed publications, which adds scientific validation to the IP claims.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Protecting Core Technology\u003c\/h3\u003e\n\u003cp\u003eThe IP is definitely valuable because it protects the specific methods used in their flagship Signatera test, which is tumor-informed MRD detection. This creates a necessary barrier to entry for competitors trying to offer similar personalized monitoring. For example, patents granted in 2025 cover methods for amplifying targeted genetic material like cfDNA, essential for these tests.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the scope of their granted IP in 2025:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue\/Example\u003c\/td\u003e\n    \u003ctd\u003eDate\/Context\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Portfolio Size\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e\u0026gt;500\u003c\/strong\u003e issued or pending patents\u003c\/td\u003e\n    \u003ctd\u003eAs of late 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2025 Patent Grant Example\u003c\/td\u003e\n    \u003ctd\u003eMethod for detecting tumor recurrence via cfDNA mutations\u003c\/td\u003e\n    \u003ctd\u003eGranted November 4, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSupporting Evidence\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e\u0026gt;325\u003c\/strong\u003e peer-reviewed publications\u003c\/td\u003e\n    \u003ctd\u003eDemonstrating test performance\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity: Breadth in Personalized MRD\u003c\/h3\u003e\n\u003cp\u003eThe breadth and depth of the portfolio, particularly in personalized MRD testing like Signatera, is rare in the diagnostics field. It’s not just one or two key patents; it’s a wide net. However, the space is highly litigious, which is a sign that others are trying to find ways around the existing IP. The recent acquisition of Foresight Diagnostics in December 2025, which brings in IP for unique phased variant technology, helps maintain this rarity by integrating new differentiation into the Signatera platform.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Time, Cost, and Litigation Risk\u003c\/h3\u003e\n\u003cp\u003eImitating this estate is difficult because it requires massive, sustained investment in R\u0026amp;D over many years to build a comparable portfolio. Still, specific patents are not invincible. In mid-2025, the U.S. District Court for the Middle District of North Carolina invalidated certain claims in two Natera patents asserted against NeoGenomics' RaDaR v1.1 test. This shows that while the overall portfolio is a moat, specific claims can be successfully challenged, eroding protection temporarily.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is that the value of the IP is tied to which specific patents are enforced. The '035 patent, for instance, was crucial for an injunction against NeoGenomics' earlier product, even while other claims were later invalidated.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Commitment to Enforcement\u003c\/h3\u003e\n\u003cp\u003eNatera demonstrates a strong organizational commitment to protecting this IP. This is evidenced by their continuous filing strategy, with new patents issued in early 2025, and their aggressive enforcement posture. They successfully secured an injunction against NeoGenomics' RaDaR v1.0 product based on the '035 patent. Furthermore, they settled a patent dispute with LabCorp mid-trial in September 2025, showing a willingness to resolve conflicts to secure their position.\u003c\/p\u003e\n\u003cp\u003eThe organization prioritizes its IP through:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eContinuous patent filing and acquisition.\u003c\/li\u003e\n\u003cli\u003eActive litigation and enforcement actions.\u003c\/li\u003e\n\u003cli\u003eStrategic M\u0026amp;A to absorb new IP.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage Evaluation\u003c\/h3\u003e\n\u003cp\u003eThe overall competitive advantage from the IP estate is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. The large volume of patents provides a strong initial moat and deters many potential entrants. However, the August 2025 litigation outcome proves that competitors can invalidate specific claims, meaning the protection is not absolute or guaranteed forever. If onboarding takes 14+ days, churn risk rises, and a competitor with a more robust, unassailable core patent could gain ground.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 2. High-Throughput, CLIA\/CAP Accredited Laboratory Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Enables high-volume processing, crucial for scaling, and ensures quality standards (CLIA\/CAP) necessary for physician trust and reimbursement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNatera processed approximately \u003cstrong\u003e893,600\u003c\/strong\u003e tests in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eTotal tests processed in CAP\/CLIA-certified labs exceeds \u003cstrong\u003e12 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin reached \u003cstrong\u003e64.9%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOncology tests performed in Q3 2025 were approximately \u003cstrong\u003e211,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSignatera average selling price (ASP) was approximately \u003cstrong\u003e$1,200\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having two major, certified facilities with significant capacity is not common among smaller diagnostics firms.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eLaboratory Location\u003c\/th\u003e\n\u003cth\u003eKey Certification\u003c\/th\u003e\n\u003cth\u003eStatus\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSan Carlos, California\u003c\/td\u003e\n\u003ctd\u003eCLIA\/CAP Accredited\u003c\/td\u003e\n\u003ctd\u003eOne of two major facilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustin, Texas\u003c\/td\u003e\n\u003ctd\u003eCLIA\/CAP Accredited\u003c\/td\u003e\n\u003ctd\u003eOne of two major facilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High initial cost and regulatory hurdles make replicating this infrastructure challenging for new entrants.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe network holds \u003cstrong\u003eISO 13485-certification\u003c\/strong\u003e in addition to CLIA and CAP accreditation.\u003c\/li\u003e\n\u003cli\u003eThe company has tests registered under the NIH Genetic Testing Registry (GTR) with various state licenses, indicating broad regulatory compliance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Labs are ISO 13485-certified and CAP-accredited, showing organized quality control systems.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as the physical infrastructure and regulatory clearances are hard to duplicate quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe operational scale supported a Q3 2025 revenue of \u003cstrong\u003e$592.2 million\u003c\/strong\u003e, a \u003cstrong\u003e34.7%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eThe company raised its 2025 annual revenue guidance by \u003cstrong\u003e$160 million\u003c\/strong\u003e at the midpoint.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 3. Signatera Molecular Residual Disease (MRD) Platform \u0026amp; Data\n\u003c\/h2\u003e\n\u003cp\u003eThe Signatera platform underpins Natera's competitive position in oncology diagnostics through its personalized, tumor-informed approach to molecular residual disease (MRD) monitoring.\u003c\/p\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe platform drives significant financial performance, evidenced by oncology tests growing 53.9% year-over-year in Q3 2025. The volume of clinical MRD units saw record sequential growth of approximately 21,500 units compared to Q2 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Value\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Tests Performed\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e211,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e137,100\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e53.9%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical MRD Tests Performed (Alternative Figure)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e202,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e130,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e56%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$592.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$439.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e34.7%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe personalized, tumor-informed nature, designed from a whole genome sequence, is a distinct offering. The Signatera Genome assay demonstrates ultra-sensitive detection capabilities.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnalytical detection limit as low as \u003cstrong\u003e1 PPM\u003c\/strong\u003e for the commercial assay.\u003c\/li\u003e\n\u003cli\u003eResearch Use Only (RUO) version detects \u003cstrong\u003ebelow 1 PPM\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eForesight's technology, expected to be incorporated, has a 95% probability of detection at 0.3 ppm, with capabilities \u003cstrong\u003ebelow 0.1 ppm\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSignatera Genome demonstrated overall longitudinal sensitivity of \u003cstrong\u003e94%\u003c\/strong\u003e and specificity of \u003cstrong\u003e100%\u003c\/strong\u003e across 5 cancer types in a pan-cancer study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe underlying technology is protected by patents, and the barrier is reinforced by accumulated clinical experience and data.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNatera utilizes methods claimed in U.S. Patent Nos. \u003cstrong\u003e11,519,035\u003c\/strong\u003e and \u003cstrong\u003e11,530,454\u003c\/strong\u003e in its Signatera product.\u003c\/li\u003e\n\u003cli\u003eNatera maintains a portfolio of more than \u003cstrong\u003e500\u003c\/strong\u003e issued or pending patents worldwide.\u003c\/li\u003e\n\u003cli\u003eThe company's proprietary real-world database (RWD) comprises data from over \u003cstrong\u003e73,000\u003c\/strong\u003e patients who underwent commercial Signatera testing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company is focused on furthering MRD leadership, evidenced by significant data presentations at major medical conferences in 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eConference\u003c\/th\u003e\n\u003cth\u003eDate Range (2025)\u003c\/th\u003e\n\u003cth\u003eData Scope\/Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCO Annual Meeting\u003c\/td\u003e\n\u003ctd\u003eMay \u003cstrong\u003e30 - June 3\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOver 25 studies presented, including interim analysis from the DARE trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASH Annual Meeting\u003c\/td\u003e\n\u003ctd\u003eDecember \u003cstrong\u003e6-9\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReal-world analysis in lymphoma evaluated 144 patients across 14 subtypes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAACR Annual Meeting\u003c\/td\u003e\n\u003ctd\u003eApril \u003cstrong\u003e25 – 30\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e8 studies shared, leveraging RWD of over 73,000 patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained advantage is provided by maintaining technological superiority in sensitivity, specifically the ability to detect down to low single-digit PPM. In a lymphoma analysis, Signatera status at the end of first-line therapy was highly prognostic of event-free survival (HR: 49.77, p\u0026lt;0.0001), outperforming standard of care PET-CT response assessment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 4. Multi-Segment Market Presence (Oncology, Women's Health, Organ Health)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies revenue risk away from a single indication, with oncology being a major driver, but women's health (Panorama) and organ health (Prospera) providing stability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While many labs serve one area, Natera is a leader across three distinct, large diagnostic markets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can enter one segment, but building credibility across all three simultaneously is tough.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The strategy is clearly articulated as a multi-segment powerhouse, supporting the 2025 revenue guidance of up to \u003cstrong\u003e$2.26 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as competitors like LabCorp or Quest could aggressively target a segment, but the established footprint is valuable now.\u003c\/p\u003e\n\u003ch3\u003eKey Segment Metrics and Financial Performance (Q3 2025)\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$592.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Tests Processed\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e893,600\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Tests Performed\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e211,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Test Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue Guidance Midpoint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.22 billion\u003c\/strong\u003e (Range: $2.18B - $2.26B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eSegment-Specific Developments\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eOncology (Signatera): Processed approximately \u003cstrong\u003e211,000\u003c\/strong\u003e tests in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eOncology (Signatera): Clinical MRD units saw sequential growth of approximately \u003cstrong\u003e21,500\u003c\/strong\u003e units over Q2 2025.\u003c\/li\u003e\n\u003cli\u003eOncology (Signatera): Average Selling Prices (ASPs) are at roughly \u003cstrong\u003e$1,200\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eWomen's Health (Panorama): Expanded Fetal Focus single-gene noninvasive prenatal test panel to cover \u003cstrong\u003e20 genes\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOrgan Health (Prospera): Trends statistically associated with outcomes, suggesting dd-cfDNA may help physicians manage patients post-rejection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 5. Proprietary cfDNA Assay Technology (e.g., LinkedSNP, Methylation)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Core technological advantage leading to high sensitivity and specificity.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAssay\/Technology\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eReported Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFetal Focus (LinkedSNP™)\u003c\/td\u003e\n\u003ctd\u003eSensitivity (Homozygous Variants, n=101)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e91%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFetal Focus (LinkedSNP™)\u003c\/td\u003e\n\u003ctd\u003eHomozygous Cases Identified\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\/5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePanorama (Older Data)\u003c\/td\u003e\n\u003ctd\u003eSensitivity (Trisomy 21)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;\u003cstrong\u003e99%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFetal RhD NIPT\u003c\/td\u003e\n\u003ctd\u003eSensitivity (Fetal RhD Positive)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFetal RhD NIPT\u003c\/td\u003e\n\u003ctd\u003eSpecificity (RhD-Negative)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific algorithms and enrichment methods (like multiplex PCR or capture by hybridization) are proprietary and protected.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIP Estate Size: Over \u003cstrong\u003e500\u003c\/strong\u003e global patents.\u003c\/li\u003e\n\u003cli\u003eOncology Patents: More than \u003cstrong\u003e110\u003c\/strong\u003e patents relating to cell-free DNA analysis for oncology testing.\u003c\/li\u003e\n\u003cli\u003e2024 Additions: \u003cstrong\u003e23\u003c\/strong\u003e patents obtained in 2024 related to oncology cfDNA analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High, as it requires deep R\u0026amp;D investment and is often covered by the IP estate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is investing heavily to advance these methods.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnticipated 2025 R\u0026amp;D Costs: Approximately \u003cstrong\u003e$575 million to $625 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 R\u0026amp;D Expenses: Part of total operating expenses of \u003cstrong\u003e$395.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 R\u0026amp;D Expenses: Part of total operating expenses of \u003cstrong\u003e$1,245.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long as they continue to innovate faster than rivals can reverse-engineer or invent around their patents.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLitigation Success: Secured a \u003cstrong\u003e$19.3 million\u003c\/strong\u003e damages award and a permanent injunction against Invitae and ArcherDX in 2024–2025.\u003c\/li\u003e\n\u003cli\u003ePatent Enforcement: Federal Circuit affirmed a preliminary injunction against NeoGenomics' RaDaR v1.0 assay in August 2025, citing infringement of U.S. Patent No. \u003cstrong\u003e11,519,035\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 6. Large, Validated Clinical Data Repository\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The data set supports payer negotiations, physician adoption, and regulatory submissions, making tests more likely to become standard-of-care.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Access to over \u003cstrong\u003e300\u003c\/strong\u003e peer-reviewed publications and extensive real-world data from their tests is a significant asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This is built over years of testing and publishing; it cannot be bought overnight.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Data is actively used to drive product roadmap, such as presenting data at major medical meetings in late 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as the volume and quality of longitudinal patient data grow with every test processed.\u003c\/p\u003e\n\u003cp\u003eThe proprietary real-world database (RWD) comprises de-identified clinical and genomic data from over \u003cstrong\u003e73,000\u003c\/strong\u003e patients who underwent commercial Signatera™ testing. Data continues to be leveraged for major presentations, including over 25 Signatera studies presented at the 2025 ASCO Annual Meeting and 8 studies presented at the 2025 AACR Annual Meeting.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2024\u003c\/th\u003e\n\u003cth\u003eFY 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Tests Processed (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e853,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e760,300\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,064,600\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Tests Processed (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~188,800\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~125,400\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Test Volume Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$546.6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$413.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,696.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~63%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~59%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe utilization of this data is demonstrated through specific clinical findings:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe RWD was used for an exploratory analysis examining CRC mutational landscape characteristics across clinical and molecular subgroups.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe RWD comprises data across \u003cstrong\u003e50+\u003c\/strong\u003e tumor histologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e70%+\u003c\/strong\u003e of the patients in the RWD have early-stage cancers.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe test detection rate in a study of early-stage CRC was \u003cstrong\u003e92%\u003c\/strong\u003e for stage 1 and \u003cstrong\u003e95%\u003c\/strong\u003e overall, at a specificity level of \u003cstrong\u003e91%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 7. Recent Acquisition of Phased Variant Technology (Foresight Diagnostics)\n\u003c\/h2\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eData\/Status Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eLOD95 of \u003cstrong\u003e0.3 ppm\u003c\/strong\u003e; detection below \u003cstrong\u003e0.1 ppm\u003c\/strong\u003e; expands into lymphoma market.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eAcquisition of patented PhasED-Seq™ technology, adding to a portfolio of \u003cstrong\u003e\u0026gt;500\u003c\/strong\u003e issued or pending patents.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eTechnology acquired; integration success subject to execution; clinical launch expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eDeal closed on \u003cstrong\u003eDecember 5, 2025\u003c\/strong\u003e; upfront payment of \u003cstrong\u003e$275 million\u003c\/strong\u003e in all-stock transaction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary; enhances Signatera's previous \u003cstrong\u003e1 ppm\u003c\/strong\u003e detection capability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcquisition Financials:\u003c\/strong\u003e Upfront payment of \u003cstrong\u003e$275 million\u003c\/strong\u003e plus up to \u003cstrong\u003e$175 million\u003c\/strong\u003e in earnouts, totaling up to \u003cstrong\u003e$450 million\u003c\/strong\u003e in an all-stock transaction.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTechnology Sensitivity:\u003c\/strong\u003e Foresight reported performance with LOD95 of \u003cstrong\u003e0.3 ppm\u003c\/strong\u003e and detection \u003cstrong\u003ebelow 0.1 ppm\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSignatera Baseline:\u003c\/strong\u003e Previous Signatera Genome assay achieved analytical detection down to \u003cstrong\u003e1 ppm\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForesight Estimated Revenue:\u003c\/strong\u003e Estimated \u003cstrong\u003e$35 million\u003c\/strong\u003e to \u003cstrong\u003e$40 million\u003c\/strong\u003e for 2025, up from \u003cstrong\u003e$20 million\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNatera Q3 2025 Performance:\u003c\/strong\u003e Revenue of \u003cstrong\u003e$592.2 million\u003c\/strong\u003e; quarterly net loss of \u003cstrong\u003e$87.5 million\u003c\/strong\u003e; processed approximately \u003cstrong\u003e893,600\u003c\/strong\u003e diagnostic tests.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNatera Market Capitalization (as of deal close):\u003c\/strong\u003e Approximately \u003cstrong\u003e$33.75 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntegration Timeline:\u003c\/strong\u003e Research-use-only version immediately available; clinical launch expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 8. Demonstrated Scalability and Improving Unit Economics (Gross Margin)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eGross margin guidance for the full 2025 year was raised to approximately \u003cstrong\u003e62% to 64%\u003c\/strong\u003e. The reported gross margin for Q3 2025 reached \u003cstrong\u003e64.9%\u003c\/strong\u003e. Full year 2024 gross margin was \u003cstrong\u003e60.3%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eOncology testing volume growth demonstrated high velocity: Q2 2025 oncology tests performed were approximately \u003cstrong\u003e188,800\u003c\/strong\u003e, a \u003cstrong\u003e50.6%\u003c\/strong\u003e increase year-over-year from Q2 2024’s \u003cstrong\u003e125,400\u003c\/strong\u003e tests. Q1 2025 clinical testing volumes surged to \u003cstrong\u003e161,000\u003c\/strong\u003e tests, a \u003cstrong\u003e52%\u003c\/strong\u003e year-over-year increase.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe scale achieved supports cost efficiencies. Signatera average selling price (ASP) reached approximately \u003cstrong\u003e$1,200\u003c\/strong\u003e in Q3 2025, up from roughly \u003cstrong\u003e$1,175\u003c\/strong\u003e in Q2 2025.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eManagement explicitly raised the gross margin guide for the full year 2025 to \u003cstrong\u003e62% to 64%\u003c\/strong\u003e following Q3 2025 results. The company noted lower cost of revenues as a driver for margin improvement, with Q3 2025 gross margin improvement attributed to efficient cost of goods sold (COGS) for Signatera tests.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained by operational leverage demonstrated through margin expansion alongside volume growth.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Gross Margin Guidance (Raised)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62% to 64%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Tests Performed (YoY Growth)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs Q2 2024\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50.6%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Tests Performed (Volume)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e188,800\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSignatera ASP\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$1,200\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSignatera Sequential Unit Growth\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q2 2025\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e21,500\u003c\/strong\u003e units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFull Year 2024 Gross Margin was \u003cstrong\u003e60.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 revenue was \u003cstrong\u003e$592 million\u003c\/strong\u003e, up \u003cstrong\u003e35%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eTotal tests processed in Q3 2025 reached \u003cstrong\u003e894,000\u003c\/strong\u003e, up \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eNatera, Inc. (NTRA) - VRIO Analysis: 9. Strong Commercial Execution and Payer Coverage Momentum\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: Drives top-line growth by ensuring physicians can order and get paid for tests, leading to raised 2025 revenue guidance to \u003cstrong\u003e$2.18 billion - $2.26 billion\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: Successfully navigating complex payer landscapes across multiple test types is a specialized, hard-to-master skill in diagnostics.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability: Competitors can hire sales teams, but building deep, established payer relationships takes significant time and success history.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: The company highlights commercial team expansion as a key driver for 2025 performance.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained, as payer relationships and established reimbursement pathways are sticky assets.\n\u003c\/p\u003e\n\u003cp\u003e\nThe strong commercial execution is evidenced by recent financial performance, including the Q2 2025 results:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Actual\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$546.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+4.6 pp\u003c\/strong\u003e (vs Q2 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSignatera Oncology Tests Processed\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e189,000\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDays Sales Outstanding (DSO)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e57\u003c\/strong\u003e days\u003c\/td\u003e\n\u003ctd\u003eCompany Record\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe company's 2025 financial outlook, based on this momentum, includes:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2025 Gross Margin guidance of \u003cstrong\u003e61% – 64%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2025 Selling, General and Administrative costs guidance of approximately \u003cstrong\u003e$0.975 billion to $1.05 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2025 Research and Development costs guidance of \u003cstrong\u003e$550 million to $590 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe Q2 2025 period generated a net cash inflow of approximately \u003cstrong\u003e$24.3 million\u003c\/strong\u003e, supporting the overall 2025 guidance for net cash inflow to be positive.\n\u003c\/p\u003e\n\u003cp\u003e\nFinance: finalize the Q4 2025 cash flow projection model by end of next week.\n\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516219252885,"sku":"ntra-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ntra-vrio-analysis.png?v=1740197488","url":"https:\/\/dcf-model.com\/pt\/products\/ntra-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}